US Bancorp DE Has $48,000 Holdings in Codexis, Inc. $CDXS

US Bancorp DE boosted its stake in Codexis, Inc. (NASDAQ:CDXS) by 11,125.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,960 shares of the biotechnology company’s stock after buying an additional 17,800 shares during the quarter. US Bancorp DE’s holdings in Codexis were worth $48,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of CDXS. Assenagon Asset Management S.A. raised its position in Codexis by 109.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 602,288 shares of the biotechnology company’s stock valued at $1,620,000 after purchasing an additional 314,424 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Codexis by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company’s stock worth $8,853,000 after acquiring an additional 211,475 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Codexis by 55.5% during the fourth quarter. Envestnet Asset Management Inc. now owns 309,713 shares of the biotechnology company’s stock worth $1,477,000 after acquiring an additional 110,541 shares during the last quarter. Deutsche Bank AG raised its position in shares of Codexis by 37.1% during the fourth quarter. Deutsche Bank AG now owns 48,172 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 13,038 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Codexis by 48.0% in the fourth quarter. Wells Fargo & Company MN now owns 47,211 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 15,303 shares during the last quarter. Institutional investors and hedge funds own 78.54% of the company’s stock.

Codexis Stock Down 4.3%

NASDAQ:CDXS opened at $2.87 on Wednesday. Codexis, Inc. has a 1 year low of $1.90 and a 1 year high of $6.08. The company has a current ratio of 5.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.71. The stock has a market cap of $259.07 million, a price-to-earnings ratio of -3.46 and a beta of 2.54. The stock has a 50-day moving average price of $2.74 and a two-hundred day moving average price of $2.79.

Codexis (NASDAQ:CDXS) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Codexis had a negative return on equity of 105.83% and a negative net margin of 113.67%.The firm had revenue of $15.33 million during the quarter, compared to analysts’ expectations of $14.18 million. As a group, equities analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Codexis from a “strong sell” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Codexis currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.